Endometrial tumour tissue and blood from 70 patients in a phase 2 clinical trial of immune checkpoint inhibitor, durvalumab, in advanced endometrial cancer PHAEDRA are being assessed for molecular subtypes and genomic profiles (PD-L1 expression by IHC, MLH1 methylation, endometrial cancer panel by WGS).